[Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of XXXX ].

@entity1 @entity298 @entity19 @entity5 @entity189 @entity356
OBJECTIVE: To evaluate the preventive potential of intraoperative or early postoperative local administration of peptide PIII into the abdominal cavity against @entity298 . METHODS: @entity1 @entity356 cells of the line GC9811 were inoculated subcutaneously into @entity19 to cause @entity189 . The 8th generation @entity5 was taken out to isolate the @entity5 cells to be inoculated into the serous membrane at the greater curvature of the stomach. Forty-eight nude BALB/C-nu/nu @entity19 underwent implantation of the 8th generation @entity5 cells into the serous membrane at the greater curvature of the stomach via minilaparotomy so as to establish models of @entity189 The 48 @entity19 were randomly divided into 3 equal groups: Group 1 (control group); Group 2, undergoing intraperitoneal perfusion of 100 microg of peptide PIII, and post-operative intraperitoneal perfusion of 2 mg/kg peptide PIII twice; and Group 3, undergoing post-operative intraperitoneal perfusion of 100 microg/kg peptide PIII twice. Six @entity19 in every group were sacrificed on the day 23 to undergo pathological examination. The other @entity19 in every group were used to evaluate the survival rate. The @entity5 -bearing @entity19 showing manifestations of failure were killed to undergo pathology. RESULTS: The weight of individual @entity5 was not significantly different among the 3 groups. The number of peritoneal metastatic nodules of Group 2 was (9.2 +/- 1.3), significantly less than those of Group 1 and 3 [(126.3 +/- 9.6) and (64.2 +/- 8.3) respectively, both P < 0.01]. The number of metastatic nodules > 2 mm of Group 2 was 1.6 +/- 0.2, significantly less then those of Groups 1 and 3 [(51.2 +/- 3.6) and (21.7 +/- 4.9) respectively, both P < 0.01]. The survival rate of Group 2 was significantly longer than those of Groups 1 and 3 (both P < 0.01). CONCLUSION: Peptide PIII does not significantly inhibit the growth of GC, but significantly reduce the peritoneal metastasis of GC. An ideal targeting chemotherapy, intra-operative application of peptide PIII into the abdominal cavity plus intraperitoneal perfusion is an attractive and promising strategy to prevent peritoneal metastasis of GC.
